The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under physician oversight.

BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation ...

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

Metabolic dysregulation has been implicated in major depressive disorder (MDD), but the causal relationship between plasma ...

Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).

Adding a daily fish oil supplement to psychotherapy showed no significant benefit over placebo for kids and teens with ...

Dr. Hans Eriksson, Chief Medical Officer, presented clinical findings from the OLIVE Phase 2b trial, which evaluated BH-200 (nelivaptan) in 338 patients with Major Depressive Disorder (MDD), using a ...

Mood symptoms alone do not account for the extent of disability associated with MDD. 12 Cognitive impairment, 1 of the 9 core symptoms of MDD (see Table 1), is significantly associated with impaired ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for ...